bluebird bio Q3 EPS $(0.66) Beats $(0.67) Estimate, Sales $12.39M Miss $13.31M Estimate
Portfolio Pulse from Benzinga Newsdesk
bluebird bio (NASDAQ:BLUE) reported Q3 losses of $(0.66) per share, beating the analyst consensus estimate of $(0.67) by 1.49 percent. This is a 29.79 percent increase over losses from the same period last year. However, the company's quarterly sales of $12.39 million missed the analyst consensus estimate of $13.31 million by 6.90 percent.
November 07, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
bluebird bio's Q3 earnings per share beat estimates, but sales missed. This mixed result could lead to uncertain short-term price movements.
While bluebird bio's earnings per share beat estimates, indicating potentially positive investor sentiment, the missed sales estimates could counteract this positivity. This mixed result could lead to uncertain short-term price movements.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100